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Immunity to pathogens requires generation of eﬀective innate and adaptive immune responses. Leishmania donovani evades these
host defense mechanisms to survive and persist in the host. A better understanding and identiﬁcation of mechanisms that L.
donovani employs for its survival is critical for developing novel therapeutic interventions that speciﬁcally target the parasite. This
paper will highlight some of the mechanisms that the parasite utilizes for its persistence and also discuss how the immune response
is regulated.
1.Introduction
Visceral leishmaniasis (VL) is caused by the intracellular
parasites Leishmania donovani and/or Leishmania infan-
tum/chagasi. In the mouse model of visceral leishmaniasis,
there is a distinct organ-speciﬁc pattern of parasite growth
during the disease progression. Infection in the liver is
characterized by a rapid increase in the parasite burden in
the ﬁrst 4 weeks of infection followed by clearance of the
parasitewithin6–8weeks.Thisself-curingmechanisminthe
liver is attributed to the development of a Th1 dominated
granulamatous response [1] characterized by high IFNγ
production by CD4 and CD8 T cells. In contrast to liver,
infection in the spleen has serious consequences demon-
strated by increased parasite burden, disruption of splenic
microarchitecture and impaired immune responses resulting
in the establishment of parasite persistence [2]. Although the
exact mechanism by which the parasite establishes chronic
infections in the spleen still remains elusive, it is now
becoming evident that the parasite targets and alters the
functions of host immune system for evasion. Some of the
mechanisms that are altered include suppression of host
protective Th1 responses, generation of defective CD8 T cells
and inhibition of dendritic cell (DC) functions [2–4]. In
addition to modifying DC and T-cell function, the parasite
also modulates B-cell function for its survival. Furthermore,
by directly interacting with diﬀerent cellular subsets, the
parasite also generates an immunosuppressive environment
by inducing IL-10 production and thus favoring its survival
in the host. In the ﬁrst part of this paper we will discuss
the above mentioned mechanisms utilized by the parasite to
evade host immune response and establish chronic infection
in the spleen. The second part of the paper will focus on the
L. donovani infection in the liver and the regulation of the
inﬂammatory response in this organ.
2. Infection in the Spleen
In the experimental model of VL, the spleen is a site
of chronic inﬂammation, characterized by parasite persis-
tence. Chronic infection of the spleen is associated with
splenomegaly and changes in the splenic microarchitecture
[2, 5, 6], which have consequences on the generation of the
immune response to the parasite [5–8]. Typically, following
encounter with antigen, dendritic cells (DCs) migrate from
the marginal zone (MZ) of the spleen to the T-cell-rich
area known as periarteriolar lymphoid sheaths (PALS). In2 Journal of Tropical Medicine
the PALS, the DCs interact with the T cells, and this
interaction results in the induction of an antigen-speciﬁc
Tc e l lr e s p o n s e[ 9]. During chronic L. donovani infection,
increased production of TNF by macrophages results in the
disruption of the splenic MZ [5]. As a consequence of this
disruption, DCs [2] and na¨ ıve T-cells [5]f a i lt om i g r a t et o
the PALS, which may results in diminished priming of T-
cells.DCs not only showanimpaired migratory capacity,but
they also down regulate important costimulatory molecules
and increasingly express inhibitory molecules [3]. Hence,
it appears that DC functions are defective at later stages
of infection. This hypothesis is supported by the fact that
adoptive transfer of LPS-activated bone marrow-derived
DCs into mice at d21p.i. results in a signiﬁcant reduction
of the splenic parasite burden [2, 10] and possibly in the
induction of protective T cellresponses. Splenomegaly is also
associatedwithdestructionofthefollicularDCnetwork [11]
and the gp38+ ﬁbroblastic reticular cell network [2]. This
disruption is particularly critical since treating or blocking it
increases the frequency of protective IFNγ-producing CD4 T
cells [12]. Conventional CD11chi splenic DCs not only show
impaired migratory capacity during chronic VL, but also
increasingly upregulate the inhibitory molecule B7-H1 dur-
ing chronic infection [3]. B7-H1 is constitutively expressed
on subsets of macrophages, thymocytes, and B cells [13], but
its expression can also be induced on DCs, epithelial, and
endothelial cells [13, 14]. B7-H1 binds to its receptor PD-
1 and inhibits T cell proliferation and cytokine production
[15]. Furthermore, B7-H1 can also induce programmed cell
deathofeﬀectorTcellsbyligationtoayetunknownreceptor
[16]. During chronic VL, antigen-speciﬁc CD8 T cells
gradually upregulate PD-1 and display signs of exhaustion
characterized by the loss of IL-2, TNF, and ﬁnally IFNγ
production. These functionally exhausted cells eventually die
[3]. Exhausted CD8 T cells have also been recently observed
in patients with diﬀuse cutaneous leishmaniasis [17]. The
functional exhaustion and deletion of antigen-speciﬁc CD8
T cells is in part induced by the upregulation of B7-H1
on splenic DCs. Indeed, in vivo blockade of B7-H1 during
chronic L. donovani infection results in increased survival
of antigen-speciﬁc CD8 T cells and also partially restores
the functional capacity of exhausted CD8 T cells [3]. The
fact that CD8 T-cell functions are not completely restored
by B7-H1 blockade suggests the involvement of additional
pathways in the suppression of cytokine production by these
cells. Other inhibitory molecules, such as LAG3 [18–20]a n d
CTLA4 [21, 22], may also be involved in this suppression.
Nevertheless, the partial recovery of CD8 T cell functions is
suﬃcient to reduce the splenic parasite burden, suggesting
thatB7-H1blockadeandthereactivationofCD8T-cellsmay
be exploited as a therapeutic intervention.
Other costimulatory and inhibitory molecules were also
shown to play a suppressive role during acute experimental
VL. Indeed, blocking of either B7-2 [23], OX40, or CTLA-4
[24, 25] results in improved T-cell responses in L. donovani
infections. Taken together, these results highlight the crucial
role of DC during VL and imply that manipulation of the
DC response to the parasite may be beneﬁcial for future
therapeutic interventions.
Another major factor contributing to progression of
disease in VL is IL-10 [10, 26–28]. The role of IL-10 in
augmenting disease has been demonstrated by studies that
show that IL-10 receptor blockade aids in abrogation of the
disease [26]. Additionally, Il10−/− mice are highly resistant
to VL [27]. During chronic infection in mice, IL-10 is
mainly expressed by CD25−FoxP3−CD4+ T cells [10], which
also produce IFNγ. These cells have also been identiﬁed in
human patients and their presence correlates with disease
progression [10]. Although there is evidence linking IL-10
and susceptibility to L. donovani infection in humans, inter-
individual diﬀerences in IL-10 production might contribute
tovariationinsusceptibilitytoL.donovani[29].Usingtrans-
genic mice expressing human IL-10 (Il10−/−/hIL10BAC), we
could investigate the role of cellular-speciﬁc IL-10 produc-
tion on susceptibility to infection. Interestingly, in these
transgenic mice IL-10 was properly regulated in the myeloid
compartment and resulted in the rescue of Il10−/− mice from
LPStoxicity.However,transgenicIL-10wasweaklyexpressed
in T cells resulting in resistance to L. donovani infection,
indicating that T-cell-derived IL-10 inhibits the control of
parasite burden in the spleen and liver. Thus, T-cell-derived
IL-10 plays an essential role in the establishment of chronic
infection [30].
IL-10 also plays an important suppressive role during the
early stages of infection. We have recently demonstrated that
IL-10 contributes to suppression of CD8 T-cell expansion
during the early stages of infection (Bankoti et al., sub-
mitted). IL-10 blockade also resulted in increased eﬀector
functions in CD8 and CD4 T cells. Several cell populations
havebeenidentiﬁedthatupregulateIL-10productionduring
L. donovani infection. These include CD4 T cells [10], NK
cells [31], macrophage [26], and DCs [32], and potentially
one of these cell populations could be responsible for
suppression of CD8 T-cell expansion and CD8 and CD4 T-
cellfunction.However,datafromourlaboratorysuggestthat
there is probably no major source of IL-10 responsible for
the suppression of T-cell function, but several IL-10 sources
contribute to it (Bankoti and St¨ ager, unpublished).
Several studies indicate that B cells have an adverse eﬀect
on disease outcome in various models of leishmaniasis [33–
36]. In experimental VL, B cells also contribute to disease
exacerbation. Indeed, in the absence of B cells, mice are
resistant to L. donovani infection [35]. The mechanism by
w h i c hBc e l l sc o n t r i b u t et op a r a s i t ep e r s i s t e n c eh a sn o ty e t
been completely deﬁned. One of the possible mechanisms by
which B cells exacerbate disease is by secretion of antibodies.
The role of antibodies in progression of disease was demon-
strated by using JH mice that produce no antibodies. Infec-
tion of JH mice with L. major resulted in smaller lesions and
limitation of the parasite burden. However, reconstituting JH
mice with anti-L. major sera at d21 postinfection resulted
in exacerbation of the disease [37, 38]. This increased
susceptibility to infection could be explained by the fact that
host IgG on the amastigote surface ligates the macrophage
FcγRs and induces IL-10 production by macrophages [37].
One of the consequences of this increased IL-10 production
is the inactivation of macrophages which further contributes
to parasite persistence. In addition to IgG, increased IgMJournal of Tropical Medicine 3
production and polyclonal B-cell activation has also been
recently demonstrated as a cause of disease exacerbation in
L. infantum infected mice during the early stages of infection
[34].
Our recent ﬁndings suggest that, in addition to inducing
IL-10 production by macrophages via antibody secretion
[37], B cells directly interact with L. donovani and this
interaction results in the suppression of protective T-cell
responses in an antibody-independent manner. Following
i.v. injection, amastigotes move to the spleen where they ini-
tially come in contact with cells of the marginal zone (MZ).
The amastigotes are primarily internalized by marginal zone
macrophages (MZM) and metallophilic macrophages (MM)
present in the MZ of the spleen [4, 9]. The marginal zone
alsoconsistsofthemarginalzoneBcells(MZBs)[39]thatare
locatedstrategicallytoencountertheparasiteearlyonduring
infection. Marginal zone B cells are noncirculating B cells
and initiate T-independent responses in response to blood
borne pathogens [40, 41]. MZBs also have the capacity to
rapidly diﬀerentiate into short lived IgM producing antibody
forming plasma cells [42]. We recently observed that L.
donovani closely interacts with B cells in vivo, inducing
activation and cluster formation (Bankoti et al., submitted).
We also observed an association between amastigotes and
cells that displayed an MZB phenotype in vivo, 24hr after
infection, suggesting that MZBs capture parasites during the
very early stages of disease. Although, the exact mechanism
of parasite capture remains unclear, it is possible that MZB
cells recognize amastigotes through surface IgM and/or
throughthecomplementreceptor2(CD21).Thisinteraction
of the parasite and MZBs resulted in the upregulation
of the costimulatory molecules CD80 and CD86 and the
production of IL-10 by two B-cell subpopulations: marginal
zoneB-cell-likecellsandregulatoryB-cells-likecells(Bankoti
et al., submitted). Moreover, in agreement with previous
report [34], B cells upon interacting with L. donovani
increasedsurfaceIgMexpressionandsecreteIgM(Bankotiet
al. submitted). In addition to inducing IL-10 production by
MZB cells, cross-linking of CD21 also induces the migration
of MZBs to the white pulp [41, 43, 44]. Hence, it is possible
that the MZB cells capture the parasite and migrate to the
white pulp where they can then transfer the antigen to the
follicular DCs [45–47]. Follicular DCs can then retain the
antigen for a long duration of time and initiate CD4 and
CD8 T-cell responses. Follicular DCs can also interact with
the follicular B cells and result in polyclonal B-cell activation
[48], which is typically observed during human VL [49–
52]. Activation of MZBs by L. donovani is detrimental to
the course of infection, since depletion of MZB results in
signiﬁcantly lower splenic parasite burdens and in stronger
CD8 and CD4 T-cell responses. This suggests that marginal
zone B cells suppress protective T-cell responses during
early stages of L. donovani infection and contribute to the
establishment of chronic disease. Although MZBs secrete
IL-10, this suppressive eﬀect is only partially mediated by
MZB-derived IL-10. Thus, it is possible that MZB inhibit
APC functions and/or induce IL-10 production by other
cell populations, such as macrophages or T cells. Further
investigations are needed to test this hypothesis.
IL-10productionbyBcellswasalsoshowntoinduceTh2
responses in a model of cutaneous leishmaniasis [53]. B cells
also produce IL-10 upon encounter with L. infantum [34];
however, this B-cell-derived IL-10 does not seem to aﬀect the
parasite burden at least at d28p.i. [34].
3.I nf ectio ninLi v e r
The liver is another main target organ in the experimental
model of VL. In contrast to the spleen that stays chronically
infected, infection in the liver is self-resolving within 6–8
weeks. Resolution of disease in the liver is associated to the
development of granuloma formation which is one of the
key features of hepatic resistance [54]. The resolution of the
infection in the liver is attributed to the development of a
Th1-dominated granulomatous response, characterized by
high IFNγ production by CD4 T cells. The Th1 response in
turn is initiated by IL-12 secreted from the DCs [9, 55]. IL-
12 is an essential cytokine in the development of protective
immunity to L. donovani, since blocking of IL-12 reduced
both the IFNγ production and granuloma formation in
the liver of infected mice [56]. Furthermore, supplementing
exogenous IL-12 to L. donovani-infected mice early during
infection decreased the liver parasite burden [57]. CD8 T
cellsalsohaveanessential rolein theclearanceof theparasite
in the liver. Indeed, depletion of CD8 T cells inhibits the
development of the granulomatous response and results in
disease exacerbation [1]. Moreover, CD8 T cells have been
shown to be mediators of resistance to rechallenge [58]. In
addition to the adaptive T-cell response, TNF production
and expression of inducible nitric oxide synthase (iNOS or
NOS2) by macrophages aid in clearing the infection. Hepatic
resistanceinVLisalsoattributedtothegenerationofreactive
nitrogen and oxygen intermediates, both of which have been
shown to play a role in containing parasite growth during
the early stages of infection [59]. These might in turn be
related to the T-cell-dependent recruitment of monocytes at
these early time points [60]. At the later stage of infection,
iNOS gene regulation appears to play an important role and
generation of NO indicates T-cell-dependent macrophage
activation [60].
Initiation of the immune response requires the recog-
nition of the parasite by the immune system. The presence
of certain molecules on the pathogens, known as pathogen-
associated molecular patterns (PAMPs) allows the immune
system to recognize the pathogen and elicit an immune
reaction. These PAMPs are recognized by Toll-like receptors
(TLRs) present on the antigen presenting cells. Recogni-
tion of a pathogen by TLRs initiates a signaling cascade
that ultimately results in the induction of cytokines. The
interferon regulatory factors (IRFs) are important parts of
this signaling chain. One of the IRFs, IRF5, is of particular
interest and has previously been demonstrated to induce
proinﬂammatory cytokines such as IL-12, TNF, and IL-6 in
response to viruses [61, 62]. This was further supported by
the fact that in Irf5−/− mice there is attenuation of type I
IFNs, TNF and IL-6 production in response to viral infection
[63–65]. We have recently demonstrated that L. donovani4 Journal of Tropical Medicine
elicits a defective Th1 responses in the liver of Irf5−/− mice
and results in fewer liver granuloma and exacerbation of
the hepatic infection [66]. Additionally, the granulomas in
Irf5−/− mice were also considerably smaller in size suggesting
a defective recruitment of inﬂammatory cells into the liver
of Irf5−/− mice. These results emphasize the importance
of IRF5 as an essential transcription factor to initiate
the inﬂammatory response following L. donovani infec-
tion. Recently, IRF5 was shown to promote inﬂammatory
macrophagepolarization[67].M1macrophages,alsoknown
as the classicallyactivated macrophages,are induced by IFNγ
to produce proinﬂammatory cytokines, for example, TNF,
IL-6, and IL-23. In addition to producing pro-inﬂammatory
cytokines, M1 macrophages also exhibit enhanced micro-
bicidal activity. M2 macrophages on the other hand are
known as alternatively activated macrophages, which pro-
duce anti-inﬂammatory cytokine and enhance tissue repair
[68, 69]. Interestingly, IRF5 inﬂuences the polarization of
macrophages. M1 macrophages have high IRF5 expression
and therefore activate genes for IL-12p40, IL-12p35, and
IL-23p19 and repress IL-10 gene [67]. Classically activated
macrophagesupontriggeringofinterferonandTLRpathway
alsoincreaseexpressionofiNOSthatresultsinproductionof
NO [70–72]. Hence, it is not surprising that iNOS protein
is not produced in the granulomas of Irf5−/− mice and
that Irf5−/− mice are more susceptible to VL. The exact
pathwaytriggeredbyL.donovanithatresultsintheinduction
of IRF5 and the mechanism by which IRF5 induces the
inﬂammatory response during L. donovani infection are still
undeﬁned. IRF5 is downstream of TLR7 and 9, but can
also be directly induced by type I IFN [73]. Thus, one
could speculate that L. donovani may trigger TLR7 and/or
TLR9 and induce IRF5 expression. It would be interesting
to examine whether IFR5 is induced by L. donovani in
Tlr9−/−Tlr7−/− double-knockout mice and whether TLR7
andTLR9haveanyoverlappingfunctions.IRF5upregulation
appears to be required by diﬀerent cells at diﬀerent time
of infection. For instance, the absence of IRF5 does not
seem to aﬀect the early development of Th1 responses. In
contrast, this transcription factor is essential for the main-
tenance of Th1 responses and is increasingly expressed in T
cells during chronic infection. Conversely, IRF5 deﬁciency
severely impaired the inﬁltration of inﬂammatory cells in
the liver already at earlier stages of infection. How this
timely expression of IRF5 regulates the immune response
and the role of IRF5 in T cells are still some of the questions
that remain unanswered and need further investigations.
Several studies have demonstrated the importance of other
IRFs during L. donovani infection. L. donovani has been
shown to induce IRF-binding activity in macrophages in
vivo [74]. Furthermore, IRF7 was shown to have a role
in regulating the killing of parasites by splenic marginal
zonemacrophage[75].Additionally,L.donovaniamastigotes
disrupt the interaction between STAT1α and importin-α5( a
nucleartransportadaptorprotein)resultingintheinhibition
of IFNγ-induced expression of IRF1 in macrophages [76].
Although these studies reveal the importance of IRFs as
an important regulator of signaling events and modulating
the outcome of disease, further investigations are required
to completely understand the exact mechanisms of IRF-
induced pathways to use it for therapeutic purposes in L.
donovani infections.
4. Conclusion
Leishmania donovani utilizes several mechanisms to evade
the host immune system depending on the cell that it
interacts with during the course of infection. Although
these events might not be chronologically linked, clearly the
parasite encounters diﬀerent cells of the immune system and
eﬃciently evades its clearance. Upon intravenous infection
with L. donovani in mice, the cells that ﬁrst come in contact
withtheparasiteinthespleenareDCs,macrophages,andthe
MZ B cells. The parasite evades these immune cells by either
interfering with proper DC function or by inducing IL-10
production by macrophages, B and T cells, resulting in an
immunosuppressive environment. The eﬀect of these altered
functions early during the disease is reﬂected by generation
of defective CD8 T and CD4 T-cell responses. Clearly there
is a dearth of knowledge regarding the complex mechanism
that the parasite utilizes to evade the immune system, and a
better understanding of the complex interaction of various
cell types with the parasite is needed to aid in development
of novel therapeutics interventions.
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